Incidence of Tendon Rupture After Collagenase Clostridium Histolyticum Injection for Treatment of Dupuytren Contracture in Adults: A Postmarketing Safety Analysis

PURPOSE: Based, in part, on the clinical study reports of tendon rupture events after collagenase clostridium histolyticum (CCH) (Xiaflex, Endo Pharmaceuticals Inc) treatment for Dupuytren contracture (DC), a Risk Evaluation and Mitigation Strategy program was instituted in 2010 by Auxilium Pharmace...

Descripción completa

Detalles Bibliográficos
Autores principales: Peimer, Clayton A., Hurley, David, Latch, Tina, Scott, Susan, Pess, Gary M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870809/
https://www.ncbi.nlm.nih.gov/pubmed/36704373
http://dx.doi.org/10.1016/j.jhsg.2022.08.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870809/
https://www.ncbi.nlm.nih.gov/pubmed/36704373
http://dx.doi.org/10.1016/j.jhsg.2022.08.013

Ejemplares similares